Athos Capital’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Athos Capital’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-930,529	Closed	-$110M	–	237
2021 Q1	$110M	Buy	930,529 +567,620	+156%	+$67.1M	18.4%	1
2020 Q4	$42.9M	Buy	362,909 +89,877	+33%	+$10.4M	11.81%	2
2020 Q3	$30.3M	Buy	273,032 +3,200	+1%	+$344K	14.59%	1
2020 Q2	$27.6M	Buy	269,832 +256,932	+1,992%	+$27.5M	18.83%	2
2020 Q1	$1.39M	Buy	12,900 +4,610	+56%	+$530K	0.97%	13
2019 Q4	$965K	Hold	8,290	–	–	0.96%	18
2019 Q3	$949K	Hold	8,290	–	–	0.93%	23
2019 Q2	$790K	Hold	8,290	–	–	0.35%	31
2019 Q1	$756K	Sell	8,290 -2,900	-26%	-$237K	0.49%	20
2018 Q4	$849K	Buy	+11,190	New	+$823K	0.84%	15
2018 Q3	–	Sell	-35,266	Closed	-$3.5M	–	36
2018 Q2	$3.5M	Buy	+35,266	New	+$3.05M	1.19%	13

Athos Capital's CBPO Position: Q2 2021 in Review

Athos Capital sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 930,529 shares — an estimated $110M sold.

Athos Capital first reported a position in CBPO in Q2 2018 and held it in 11 quarters. The position peaked at $110M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

Athos Capital reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
Athos Capital sold 930,529 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $110M.
Athos Capital first reported a position in China Biologic Products Holdings, Inc. in Q2 2018 and held it in 11 quarters.
Athos Capital's China Biologic Products Holdings, Inc. position peaked at $110M in Q1 2021.
0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Athos Capital's 13F filing for Q2 2021, filed 12 Aug 2021.